Get the Stockscreener App
15.67
3.09%
0.47
Intellia Therapeutics Inc stock is traded at $15.67, with a volume of 8.84M.
It is up +3.09% in the last 24 hours and up +23.48% over the past month.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
See More
Previous Close:
$15.20
Open:
$15.525
24h Volume:
8.84M
Relative Volume:
1.44
Market Cap:
$2.19B
Revenue:
$67.67M
Net Income/Loss:
$-412.69M
P/E Ratio:
-4.095
EPS:
-3.8266
Net Cash Flow:
$-395.87M
1W Performance:
+26.88%
1M Performance:
+23.48%
6M Performance:
+76.46%
1Y Performance:
+63.23%
1-Day Range:
$15.04
$16.20
1-Week Range:
$11.95
$16.73
52-Week Range:
$7.95
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Name
Intellia Therapeutics Inc
Sector
Industry
Phone
857-285-6200
Address
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
15.67 | 2.19B | 67.67M | -412.69M | -395.87M | -3.8266 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| Nov-12-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Nov-11-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-07-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-28-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-28-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-27-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-27-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-06-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Apr-21-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-05-25 | Initiated | H.C. Wainwright | Buy |
| Feb-28-25 | Downgrade | Goldman | Neutral → Sell |
| Feb-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-27-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-23-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Apr-13-23 | Initiated | Canaccord Genuity | Buy |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Mar-14-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-24-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-19-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Sell |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Jun-16-22 | Initiated | BofA Securities | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Feb-18-22 | Initiated | William Blair | Outperform |
| Feb-07-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-22 | Initiated | Cowen | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
| Oct-05-21 | Initiated | Guggenheim | Buy |
| Sep-24-21 | Initiated | Stifel | Buy |
| Jun-28-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-11-21 | Initiated | H.C. Wainwright | Buy |
| May-07-21 | Upgrade | ROTH Capital | Neutral → Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
| Dec-22-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-27-20 | Initiated | Truist | Buy |
| Oct-14-20 | Initiated | Wells Fargo | Overweight |
| Sep-18-20 | Initiated | Goldman | Buy |
| Feb-28-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-14-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-01-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-09-19 | Initiated | Robert W. Baird | Outperform |
| Jun-10-19 | Initiated | ROTH Capital | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Nov-02-18 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-29-18 | Initiated | Credit Suisse | Neutral |
| Sep-21-18 | Initiated | Raymond James | Mkt Perform |
| May-15-18 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-08-18 | Initiated | JMP Securities | Mkt Outperform |
| Nov-01-17 | Reiterated | Jefferies | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-05-16 | Upgrade | Jefferies | Hold → Buy |
View All
Intellia Therapeutics Inc Stock (NTLA) Latest News
NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late - Stocktwits
NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy - Stocktwits
Strength seen in Intellia Therapeutics (NTLA): Can its 23.2% jump turn into more strength? - MSN
Intellia Therapeutics (NTLA) Surges 12.9% Amid Positive Market M - GuruFocus
Intellia Therapeutics (NTLA) Sees 10.7% Surge in Stock Price - GuruFocus
NTLA Stock Climbs As Phase 3 CRISPR Data Turn Heads - StocksToTrade
NTLA Stock Jumps As Intellia’s HAE Gene-Editing Data Impresses Wall Street - timothysykes.com
CCORF Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $49 - Moomoo
Analysts Offer Insights on Healthcare Companies: enGene Holdings (ENGN) and Intellia Therapeutics (NTLA) - The Globe and Mail
Why Is NTLA Stock Jumping 5% Premarket Today? - Stocktwits
This Stock Is Up 58% This Year. Is It too Late to Buy? - The Motley Fool
This Stock Is Up 58% This Year. Is It too Late to Buy? - The Motley Fool
Physician Views Preview: Can Intellia's lonvo-z turn CRISPR promise into HAE practice? - FirstWord Pharma
NTLA Maintained by Canaccord Genuity -- Price Target Stays at $4 - GuruFocus
NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up - The Globe and Mail
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $19 to $49 - Moomoo
Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength? - Yahoo! Finance Canada
Canaccord reiterates Intellia stock rating on positive trial data By Investing.com - Investing.com Nigeria
Intellia’s gene editor ‘keeps pace’ with Ionis in hereditary angioedema - BioSpace
Canaccord reiterates Intellia stock rating on positive trial data - Investing.com
Analysts Conflicted on These Healthcare Names: Incyte (INCY), Intellia Therapeutics (NTLA) and Halozyme (HALO) - The Globe and Mail
BofA Securities Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Maintains Target Price $19 - Moomoo
Analysts’ Top Healthcare Picks: Intellia Therapeutics (NTLA), Electrocore (ECOR) - The Globe and Mail
Intellia Therapeutics Inc (NTLA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Intellia's Treatment Candidate Shows Promising Results - Intellectia AI
Intellia Therapeutics (NTLA) Skyrockets 23% on Encouraging Lonvo-Z Results - Insider Monkey
Intellia Therapeutics Stock Jumps as CRISPR Therapy Data Put FDA Filing in Focus - TechStock²
Intellia Therapeutics jumps after additional Phase 3 HAE data and peer-reviewed publication reinforce lonvo-z outlook - Quiver Quantitative
Why is Intellia Therapeutics stock surging today? By Investing.com - Investing.com Canada
Intellia Therapeutics | 8-K: Current report - Moomoo
NTLA Reiterated by Wedbush -- Price Target Maintained at $12.00 - GuruFocus
Intellia Therapeutics options trading jumps to 7,041 contracts By Investing.com - Investing.com South Africa
NTLA Reiterated by Citizens -- Price Target Maintained at $30 - GuruFocus
Intellia Therapeutics options trading jumps to 7,041 contracts - Investing.com
Goldman Sachs Maintains Intellia Therapeutics(NTLA.US) With Sell Rating, Maintains Target Price $9 - Moomoo
Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder - Benzinga
Intellia Reports Strong Phase 3 Results for lonvo-z, 87% fewer monthly attacks; BLA rolling, U.S. launch H1 2027 - TradingView
Phase 3 HAELO data support Intellia (NTLA) lonvo-z as potential one-time therapy - Stock Titan
Why is NTLA stock jumping 5% premarket today? - MSN
H.C. Wainwright reiterates Intellia stock rating on positive trial data By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Intellia stock rating on positive trial data - Investing.com
Positive Phase III results for Intellia’s lonvo-z - The Pharma Letter
NTLA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
Citizens reiterates Intellia stock rating on positive trial data By Investing.com - Investing.com Nigeria
Citizens reiterates Intellia stock rating on positive trial data - Investing.com
H.C. Wainwright Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $25 - Moomoo
William Blair Maintains Intellia Therapeutics(NTLA.US) With Buy Rating - Moomoo
Intellia Therapeutics (NTLA) down 7.9% since last earnings report: Can it rebound? - MSN
Intellia Therapeutics (NTLA) Reports Promising Phase 3 Trial Res - GuruFocus
Why Intellia Therapeutics (NTLA) Is Down 10.6% After Advancing Lonvo-z Toward FDA Review And Commercialization - Sahm
Intellia presents Phase 3 results for HAE gene therapy lonvo-z - Investing.com UK
Intellia Therapeutics Inc Stock (NTLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Intellia Therapeutics Inc Stock (NTLA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Clark Eliana | EVP, Chief Technical Officer |
Mar 02 '26 |
Sale |
13.78 |
607 |
8,364 |
93,864 |
| LEONARD JOHN M | President and CEO |
Jan 05 '26 |
Sale |
9.21 |
34,146 |
314,485 |
1,013,339 |
| Schultes Birgit C | EVP, Chief Scientific Officer |
Jan 05 '26 |
Sale |
9.21 |
8,508 |
78,359 |
98,533 |
| BASTA JAMES | EVP, General Counsel |
Jan 05 '26 |
Sale |
9.21 |
10,397 |
95,756 |
101,528 |
| Cohen Fred E | Director |
Jan 05 '26 |
Buy |
9.35 |
150,000 |
1,402,500 |
207,453 |
| Lebwohl David | EVP, Chief Medical Officer |
Jan 05 '26 |
Sale |
9.21 |
11,903 |
109,627 |
121,249 |
| Clark Eliana | EVP, Chief Technical Officer |
Jan 05 '26 |
Sale |
9.21 |
9,515 |
87,633 |
87,118 |
| Dulac Edward J III | EVP, Chief Financial Officer |
Jan 05 '26 |
Sale |
9.21 |
6,379 |
58,751 |
99,683 |
| Dube Michael P | VP, Chief Accounting Officer |
Jan 05 '26 |
Sale |
9.21 |
2,989 |
27,529 |
52,277 |
| LEONARD JOHN M | President and CEO |
Dec 11 '25 |
Option Exercise |
6.83 |
49,959 |
341,220 |
1,127,074 |
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):